Titan Biotech Limited (BOM:524717)
India · Delayed Price · Currency is INR 434.10
+5.65 (1.32%)
At close: Jun 19, 2026
Titan Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,062 | 1,565 | 1,641 | 1,440 | 1,235 |
| 2,062 | 1,565 | 1,641 | 1,440 | 1,235 | |
Revenue Growth (YoY) | 31.79% | -4.64% | 13.94% | 16.55% | -13.14% |
Cost of Revenue | 961.95 | 741.94 | 769.36 | 710.43 | 598.28 |
Gross Profit | 1,100 | 822.57 | 871.36 | 729.57 | 637.21 |
Selling, General & Admin | 323.62 | 310.18 | 267.96 | 209.68 | 148.78 |
Other Operating Expenses | 390.3 | 259.6 | 262.02 | 225.04 | 176.6 |
Operating Expenses | 763.17 | 611.47 | 563.29 | 461.52 | 349.08 |
Operating Income | 336.78 | 211.1 | 308.08 | 268.05 | 288.13 |
Interest Expense | -9.14 | -4.4 | -7.96 | -4.5 | -5.99 |
Interest & Investment Income | - | 5.1 | 0.86 | 0.44 | 1.13 |
Earnings From Equity Investments | 24.38 | 32.61 | 11.9 | 38.19 | - |
Other Non Operating Income (Expenses) | 54.1 | 26.25 | 8.69 | 16.68 | 6.44 |
EBT Excluding Unusual Items | 406.13 | 270.65 | 321.56 | 318.87 | 289.71 |
Gain (Loss) on Sale of Investments | - | 5.63 | 5.63 | 0.49 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.02 |
Pretax Income | 406.13 | 276.28 | 327.19 | 319.35 | 289.69 |
Income Tax Expense | 107.27 | 60.96 | 78.66 | 70.91 | 72.85 |
Earnings From Continuing Operations | 298.85 | 215.32 | 248.53 | 248.44 | 216.84 |
Net Income | 298.85 | 215.32 | 248.53 | 248.44 | 216.84 |
Net Income to Common | 298.85 | 215.32 | 248.53 | 248.44 | 216.84 |
Net Income Growth | 38.80% | -13.36% | 0.03% | 14.57% | -28.52% |
Shares Outstanding (Basic) | 41 | 41 | 41 | 41 | 41 |
Shares Outstanding (Diluted) | 41 | 41 | 41 | 41 | 41 |
Shares Change (YoY) | 0.04% | - | - | - | - |
EPS (Basic) | 7.23 | 5.21 | 6.01 | 6.01 | 5.25 |
EPS (Diluted) | 7.23 | 5.21 | 6.01 | 6.01 | 5.25 |
EPS Growth | 38.74% | -13.35% | 0.02% | 14.57% | -28.52% |
Free Cash Flow | 229.77 | 107.55 | 16.61 | 84.45 | 157.29 |
Free Cash Flow Per Share | 5.56 | 2.60 | 0.40 | 2.04 | 3.81 |
Dividend Per Share | 0.500 | 0.400 | 0.400 | 0.360 | 0.300 |
Dividend Growth | 25.00% | - | 11.11% | 20.00% | - |
Gross Margin | 53.35% | 52.58% | 53.11% | 50.66% | 51.58% |
Operating Margin | 16.33% | 13.49% | 18.78% | 18.62% | 23.32% |
Profit Margin | 14.49% | 13.76% | 15.15% | 17.25% | 17.55% |
Free Cash Flow Margin | 11.14% | 6.87% | 1.01% | 5.86% | 12.73% |
EBITDA | 386.04 | 248 | 336.52 | 289.21 | 307.71 |
EBITDA Margin | 18.72% | 15.85% | 20.51% | 20.08% | 24.91% |
D&A For EBITDA | 49.25 | 36.9 | 28.44 | 21.16 | 19.58 |
EBIT | 336.78 | 211.1 | 308.08 | 268.05 | 288.13 |
EBIT Margin | 16.33% | 13.49% | 18.78% | 18.62% | 23.32% |
Effective Tax Rate | 26.41% | 22.07% | 24.04% | 22.20% | 25.15% |
Revenue as Reported | 2,116 | 1,604 | 1,658 | 1,459 | 1,245 |
Advertising Expenses | - | 40.72 | 26.12 | 26.42 | 5.48 |